CytoMed Therapeutics (GDTC) announced that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology of TC BioPharm, a subsidiary of TC BioPharm (TCBP). This follows CytoMed’s announcement on October 14, 2025 regarding its proposed acquisition of potentially synergistic assets from TCBL.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC:
- CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India
- Cytomed Therapeutics secures investment for subsidiary LongevityBank
- CytoMed Therapeutics Secures Investment and Advances China Strategy
- CytoMed Therapeutics’ ANGELICA Trial: A New Frontier in Cancer Treatment
- CytoMed Therapeutics’ Chairman Boosts Stake Amid Biotherapeutics Growth